Publications
-
- Conference presentation
- [AACR 2026] Overcoming target heterogeneity in gastric cancer with an eKiHengineered CLDN18.2×HER2 bispecific ADC
-
- Conference presentation
- [AACR 2026] Overcoming EMT-associated tumor progression in solid tumor with an eKiH-engineered HER2×AXL bispecific ADC
-
- Conference presentation
- [AACR 2026] NECTIN4×PD-L1 bispecific antibody-drug conjugate integrating checkpoint blockade and targeted cytotoxicity for urothelial carcinoma and head and neck squamous cell carcinoma
-
- Conference presentation
- [AACR 2026] Integrated platform for developing bispecific antibody drug conjugates (bsADC) for optimal targeting of heterogenous solid tumors
-
- Conference presentation
- [AACR 2026] DA-3501 (AT-211): Evaluation of immune-mediated antitumor activity and combination immunotherapy potential of a site-specific CLDN18.2-targeting antibody-drug conjugate (ADC)
-
- Conference presentation
- [AACR 2026] DA-4531: A Novel PARP7 Inhibitor Exhibits Dual Antitumor Activity Through Immune Activation and Tumor-Intrinsic Growth Inhibition
-
- Conference presentation
- [AACR 2026] DA-4531: Dual mechanisms of PARP7 inhibition driving potent antitumor activity
-
- Conference presentation
- [AACR 2026] DA-4701: Rationally designed Allosteric EGFR Degrader SC3499 (IN-207375) Selectively Eliminates Mutant EGFR and Overcomes osimertinib resistance in Non-Small Cell Lung Cancer
-
- Conference presentation
- [AACR 2026] DA-4701: Discovery of SC3613 (IN-207387), a Mutant-Selective EGFR degrader, Exhibits Potent Anti-tumor Activity and Improved Safety Profile in EGFR TKI-Resistance in NSCLC
-
- Conference presentation
- [AACR 2025] DA-4701: Discovery of SC2073 (IN-207039), a potent and mutant selective EGFR degrader that overcomes 3rd generation EGFR inhibitors resistance in NSCLC
